MX360141B - Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. - Google Patents

Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.

Info

Publication number
MX360141B
MX360141B MX2014009751A MX2014009751A MX360141B MX 360141 B MX360141 B MX 360141B MX 2014009751 A MX2014009751 A MX 2014009751A MX 2014009751 A MX2014009751 A MX 2014009751A MX 360141 B MX360141 B MX 360141B
Authority
MX
Mexico
Prior art keywords
antibodies
same
treat cancer
avb6
integrin avb6
Prior art date
Application number
MX2014009751A
Other languages
English (en)
Other versions
MX2014009751A (es
Inventor
Ryan Maureen
Sussman Django
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2014009751A publication Critical patent/MX2014009751A/es
Publication of MX360141B publication Critical patent/MX360141B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

La presente invención se refiere a anticuerpos que se unen específicamente a integrina avß6. Los anticuerpos son útiles para el tratamiento y el diagnóstico de diversos tipos de cáncer, así como la detección de avß6.
MX2014009751A 2012-02-17 2013-02-14 Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. MX360141B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600499P 2012-02-17 2012-02-17
US201261602511P 2012-02-23 2012-02-23
PCT/US2013/026087 WO2013123152A2 (en) 2012-02-17 2013-02-14 ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER

Publications (2)

Publication Number Publication Date
MX2014009751A MX2014009751A (es) 2015-02-24
MX360141B true MX360141B (es) 2018-10-24

Family

ID=48984888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009751A MX360141B (es) 2012-02-17 2013-02-14 Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.

Country Status (14)

Country Link
US (5) US9493566B2 (es)
EP (1) EP2814509B1 (es)
JP (1) JP6273214B2 (es)
KR (1) KR102084806B1 (es)
CN (2) CN104220094A (es)
AU (1) AU2013221585B2 (es)
BR (1) BR112014019861A2 (es)
CA (1) CA2862319C (es)
EA (1) EA031069B1 (es)
HK (1) HK1211035A1 (es)
IL (1) IL233742B (es)
MX (1) MX360141B (es)
SG (1) SG11201404354UA (es)
WO (1) WO2013123152A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143411A2 (en) 2008-05-23 2009-11-26 Siwa Corporation Methods, compositions and apparatus for facilitating regeneration
JP6527508B2 (ja) * 2013-10-01 2019-06-05 メディミューン リミテッド αＶβ６を過剰発現する癌を治療及び診断する方法
KR102645430B1 (ko) 2013-10-15 2024-03-11 씨젠 인크. 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
JP6716461B2 (ja) 2014-02-17 2020-07-01 シアトル ジェネティックス， インコーポレイテッド 親水性抗体−薬物コンジュゲート
US20170233452A1 (en) * 2014-04-23 2017-08-17 Immusoft Corporation Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
CA3006000A1 (en) 2015-12-04 2017-06-08 Seattle Genetics, Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CN109071675A (zh) 2016-02-19 2018-12-21 Siwa有限公司 使用高级糖化终产物(age)的抗体治疗癌症、杀死转移性癌细胞和预防癌症转移的方法和组合物
KR102626498B1 (ko) 2016-03-25 2024-01-19 씨젠 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
CA3032147A1 (en) 2016-08-09 2018-02-15 Seattle Genetics, Inc. Drug conjugates with self-stabilizing linkers having improved physiochemical properties
EA201990890A1 (ru) 2016-10-18 2019-10-31 Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида
CA3039618A1 (en) 2016-11-01 2018-05-11 Arrowhead Pharmaceuticals, Inc. Alpha-v beta-6 integrin ligands and uses thereof
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
JP2020512312A (ja) 2017-03-24 2020-04-23 シアトル ジェネティックス， インコーポレイテッド グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体
JP2020516648A (ja) * 2017-04-13 2020-06-11 シワ コーポレーション ヒト化モノクローナル終末糖化産物抗体
JP7425606B2 (ja) 2017-04-27 2024-01-31 シージェン インコーポレイテッド 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
JP7445594B2 (ja) * 2017-11-01 2024-03-07 アローヘッド ファーマシューティカルズ インコーポレイテッド インテグリンリガンドおよびその使用
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
KR20200122351A (ko) 2018-02-20 2020-10-27 시애틀 지네틱스, 인크. 소수성 아우리스타틴 f 화합물 및 그의 접합체
US11827709B2 (en) * 2019-12-05 2023-11-28 Seagen Inc. Anti-AVB6 antibodies and antibody-drug conjugates
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
EP4132588A1 (en) 2020-04-10 2023-02-15 Seagen Inc. Charge variant linkers
EP4326333A1 (en) 2021-04-20 2024-02-28 Seagen Inc. Modulation of antibody-dependent cellular cytotoxicity
AU2022283467A1 (en) 2021-05-28 2023-12-07 Seagen Inc. Anthracycline antibody conjugates
US20230381321A1 (en) 2022-03-17 2023-11-30 Seagan Inc., Camptothecin conjugates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
DE69828614T2 (de) 1997-08-08 2006-02-09 The Regents Of The University Of California, Oakland Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6
ES2437875T3 (es) * 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
WO2003100033A2 (en) * 2002-03-13 2003-12-04 Biogen Idec Ma Inc. ANTI-αvβ6 ANTIBODIES
UA90242C2 (ru) * 2002-03-13 2010-04-26 Байоджен Айдек Ма Инк. МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С αVβ6
WO2003087340A2 (en) 2002-04-12 2003-10-23 Raven Biotechnologies, Inc. Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
US7241598B2 (en) * 2004-06-29 2007-07-10 The Chinese University Of Hong Kong Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
EP1828251B1 (en) * 2004-10-05 2012-09-26 Janssen Alzheimer Immunotherapy Methods and compositions for improving recombinant protein production
US8603483B2 (en) * 2004-12-09 2013-12-10 Janssen Biotech, Inc. Anti-integrin immunoconjugates, methods and uses
ES2429340T3 (es) 2005-03-10 2013-11-14 Morphotek, Inc. Anticuerpos anti-mesotelina
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
WO2007026000A2 (en) 2005-08-31 2007-03-08 Novo Nordisk Health Care Ag Human fvii monoclonal antibodies binding the gla domain and use thereof
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
ES2746925T3 (es) 2006-08-03 2020-03-09 Medimmune Ltd Anticuerpos dirigidos hacia alfaVbeta6 y uso de los mismos
JP2010506944A (ja) 2006-10-19 2010-03-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンαＶβ６のアンタゴニストを用いる慢性喘息の処置および予防
US9274119B2 (en) * 2008-01-11 2016-03-01 The University Of Tokyo Anti-CLDN6 antibody
BRPI0906498A2 (pt) * 2008-01-22 2015-07-14 Biogen Idec Inc Anticorpo ron e seus usos
CN101959929B (zh) 2008-03-27 2013-05-01 泰尔茂株式会社 生物体吸收性材料及使用其的生物体内留置物
EP2279209A2 (en) 2008-05-09 2011-02-02 Ablynx NV Amino acid sequences directed against integrins and uses thereof
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
WO2011046309A2 (en) * 2009-10-12 2011-04-21 Korea Research Institute Of Bioscience And Biotechnology A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof
KR101138460B1 (ko) 2009-10-12 2012-04-26 한국생명공학연구원 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
WO2012068540A2 (en) 2010-11-19 2012-05-24 Toshio Imai Neutralizing anti-ccl20 antibodies
WO2013148316A1 (en) 2012-03-29 2013-10-03 Biogen Idec Ma Inc. Biomarkers for use in integrin therapy applications

Also Published As

Publication number Publication date
CN105017420A (zh) 2015-11-04
SG11201404354UA (en) 2014-10-30
JP2015509938A (ja) 2015-04-02
CA2862319C (en) 2021-11-30
US20160376368A1 (en) 2016-12-29
EA201491541A1 (ru) 2016-05-31
IL233742A0 (en) 2014-09-30
CN105017420B (zh) 2019-05-28
IL233742B (en) 2019-08-29
EP2814509A2 (en) 2014-12-24
CA2862319A1 (en) 2013-08-22
WO2013123152A2 (en) 2013-08-22
KR20140127875A (ko) 2014-11-04
MX2014009751A (es) 2015-02-24
US20210340260A1 (en) 2021-11-04
US20160009806A1 (en) 2016-01-14
EP2814509B1 (en) 2018-05-16
AU2013221585B2 (en) 2017-03-30
AU2013221585A1 (en) 2014-08-14
WO2013123152A3 (en) 2014-11-13
CN104220094A (zh) 2014-12-17
HK1211035A1 (en) 2016-05-13
US9493566B2 (en) 2016-11-15
BR112014019861A2 (pt) 2017-07-04
KR102084806B1 (ko) 2020-03-04
EA031069B1 (ru) 2018-11-30
US20230242648A1 (en) 2023-08-03
US20200031938A1 (en) 2020-01-30
JP6273214B2 (ja) 2018-01-31
EP2814509A4 (en) 2015-12-09

Similar Documents

Publication Publication Date Title
MX360141B (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
MX2020010639A (es) Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
NZ702748A (en) Cd33 antibodies and use of same to treat cancer
TN2015000396A1 (en) Antibody drug conjugates
SG2014008304A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
SG10201704992SA (en) Lsr antibodies, and uses thereof for treatment of cancer
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
MX2013013226A (es) Anticuerpos c-kit y usos de los mismos.
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
EA201400178A1 (ru) Лечение рака молочной железы
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
IN2014DN09717A (es)
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
MX362497B (es) Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
GB201212690D0 (en) Materials and methods for treating pten mutated or deficient cancer
IL232339A0 (en) 32rf10c antibodies, and their uses for cancer treatment
TR201905240T4 (tr) LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı.
IL232340A0 (en) lsr antibodies, and their uses for cancer treatment

Legal Events

Date Code Title Description
FG Grant or registration